Clinical Outsourcing
Table 1: Select trade deals in the CRO sector
Target Country of target Buyer Country of buyer Date of announcement (2008)
Tangent Data Romania Nicholas Piramal India October
Simbec UK Algorithme Canada August
Msource Belgium TÜV SÜD Germany July
International Oncology Network US Veeda Clinical Research UK/India July
(ION) Clinical Research
MediQuest Serbia Worldwide Clinical Trials US July
Prologue Research International US Encorium US June
DecisionLine Canada Kendle US June
Biologie et Industrie France Veeda Clinical Research UK/India May
Omega Mediation Group Europe/Israel SIRO Clinpharm India April
Lege Artis Russia i3 Research US April
Drug Development Solutions UK Chiltern International UK February
Healthcare Discoveries US Icon Clinical Ireland February
DUX Consulting Czech Republic/Slovakia Kiecana Clinical Research Poland February
InnoPharm Russia PPD US February
Source: Ernst & Young
or grow their operational footprint and Clinical Research of the US. Through these Metrics Research thereby enabling Synergy to
capabilities in new territories. With its large transactions, Veeda strengthened its capability conduct trials in the latter company’s home
population (more than 300 million) and in Western Europe and added 50 clinical country Pakistan. In September 2007, Synergy
strengthening economies, recent M&A activity research sites in the US. In a similar fashion, entered into a similar partnership with an
has been focused on assets in Central and the Indian CRO SIRO Clinpharm acquired Indian CRO Neeman Medical International.
Eastern Europe as companies seek to capitalise Omega Mediation Group in April 2008, a Another alliance forged between regional
on the region’s high growth potential. business with presence in f_i ve European players was Suven Life Sciences’ April 2008
Worldwide Clinical Trials (WCT) recently countries and Israel. In July 2007 SIRO deal with the Beijing-based company VPSCRO
acquired MediQuest, a Serbian business acquired Global Client Partners, a US CRO. to conduct clinical trial services in India
based in Belgrade, and Evidence Clinical and and China.
Pharmaceutical Research, a company with
JVs and alliance networks
Alliances that bridge the West and
presence in Russia, Ukraine and Georgia.
Small regional companies have been building
Eastern markets have also become more
US-based i3 acquired Lege Artis which, with
alliance networks in a bid to compete with
common. Recent deals include US-based MPI
operations in Russia, Belarus and Ukraine
larger global CROs. This type of activity
Research’s alliance with Shanghai Medicilon to
complemented i3’s existing operations in the
appears to be particularly prevalent in Eastern
establish a preclinical research facility based
Czech Republic, Poland and Serbia. In February
markets and might be regarded as a defensive
in Shanghai that will meet US FDA and other
2008, Pharmaceutical Product Development
measure in light of growing competition from
major regulatory standards. There was also
(PPD) strengthened its presence in CEE with
western CROs setting up operations in India
the US f_i rm Immtech and Beijing Capital
the acquisition of Russia’s InnoPharm, gaining
and China.
Medical University’s JV established to provide
operations in that country and Ukraine.
In May 2007, for instance, a trio of
contract research services in China.
The entry of competition from well
Chinese companies – Sundia MediTech,
established western CROs is one factor
United Pharmatech and HD Biosciences, adding depth and breadth
driving local players to shore up their market
all of Shanghai – entered into an alliance to Deals are also being driven by the need to
presence, a good example being Polish Kiecana
consolidate their position in the local market. build capability, for example in a particular
Clinical Research’s acquisition of Czech In February 2008, UK-based NovaSecta clinical phase, therapeutic area, treatment
DUX Consulting. joined the alliance and was followed two setting, patient population or technology.
Yet the US and Western Europe remain months later by Tigermed Consulting, A key driver is signif_i cant customer demand
critical pharmaceutical markets and another Shanghai f_i rm, which added clinical for Phase I capabilities and high growth in this
transactions are not solely being driven by development, data management and statistical segment. For example, in June 2008, Kendle
Western companies looking to emerging support services to the alliance’s portfolio. announced the $24 million acquisition of
markets; the reverse is also happening. In a similar initiative aimed at competing DecisionLine, a CNS-focused Phase I CRO
Notably, Indian CROs are buying into Europe with the ability of global CROs to provide based in Toronto, Canada. The deal brought
and the US. During 2008, the oncology- large multicentre trials, the Russian CRO Kendle an 82-bed facility, staff scientists,
focused Indian CRO Veeda Clinical Research Synergy Research has been forming nurses and clinical development personnel.
made two such transactions, acquiring the partnerships to extend its geographical reach, Similarly Chiltern International’s acquisition
Paris-based CRO Biologie et Industrie and with a particular focus on Asia. In June 2008, of Scotland’s Drug Development Solutions
International Oncology Network (ION) the company formed a partnership with secured Chiltern a Phase I unit with 42 beds
110
www.scripnews.com/supplements Scrip 100
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128